Immunovia Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de Immunovia.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Medical Equipment	23.5%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Here's Why We're Not Too Worried About Immunovia's (STO:IMMNOV) Cash Burn Situation

Jan 18

We Think Immunovia (STO:IMMNOV) Can Afford To Drive Business Growth

Aug 28

What Kind Of Investors Own Most Of Immunovia AB (publ) (STO:IMMNOV)?

Mar 09

Here's Why We're Not Too Worried About Immunovia's (STO:IMMNOV) Cash Burn Situation

Feb 03

Immunovia AB (publ)'s (STO:IMMNOV) Intrinsic Value Is Potentially 72% Above Its Share Price

Dec 30

Insider Buying: The Immunovia AB (publ) (STO:IMMNOV) Director Just Bought kr293k Worth Of Shares

Dec 03

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como Immunovia no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

OM:IMMNOV - Estimaciones futuras de los analistas y datos financieros pasados (SEK Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
3/31/2024	2	-261	-133	-132	N/A
12/31/2023	2	-309	-148	-147	N/A
9/30/2023	2	-328	-171	-170	N/A
6/30/2023	2	-312	-173	-172	N/A
3/31/2023	1	-176	-170	-169	N/A
12/31/2022	1	-168	-177	-176	N/A
9/30/2022	1	-148	-177	-174	N/A
6/30/2022	1	-161	-180	-175	N/A
3/31/2022	1	-177	-181	-169	N/A
12/31/2021	1	-156	-177	-153	N/A
9/30/2021	1	-155	-173	-138	N/A
6/30/2021	0	-157	-176	-133	N/A
3/31/2021	0	-142	-171	-123	N/A
12/31/2020	0	-146	-168	-121	N/A
9/30/2020	0	-133	-154	-108	N/A
6/30/2020	0	-120	-150	-106	N/A
3/31/2020	0	-116	-143	-105	N/A
12/31/2019	0	-115	-129	-92	N/A
9/30/2019	-19	-108	-128	-95	N/A
6/30/2019	-13	-99	-122	-89	N/A
3/31/2019	-6	-96	-121	-83	N/A
12/31/2018	0	-87	-121	-84	N/A
9/30/2018	29	-76	-117	-75	N/A
6/30/2018	26	-70	-102	-63	N/A
3/31/2018	25	-55	-90	-55	N/A
12/31/2017	24	-45	N/A	-46	N/A
9/30/2017	23	-35	N/A	-36	N/A
6/30/2017	24	-28	N/A	-25	N/A
3/31/2017	25	-20	N/A	-11	N/A
12/31/2016	24	-15	N/A	-12	N/A
9/30/2016	22	-11	N/A	-8	N/A
6/30/2016	22	-9	N/A	-8	N/A
3/31/2016	19	-8	N/A	-12	N/A
12/31/2015	17	-7	N/A	-7	N/A
9/30/2015	12	-9	N/A	-7	N/A
6/30/2015	7	-10	N/A	-7	N/A
3/31/2015	4	-9	N/A	-8	N/A
12/31/2014	0	-9	N/A	-8	N/A
12/31/2013	1	-2	N/A	N/A	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de IMMNOV es superior a la tasa de ahorro (0.9%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de IMMNOV crezcan más rápidamente que el mercado Swedish

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de IMMNOV crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de IMMNOV crezcan más rápidamente que el mercado de Swedish.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de IMMNOV crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de IMMNOV se prevé que sea elevada dentro de 3 años.

Immunovia Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Price target decreased to kr110

Price target decreased to kr215

Consensus forecasts updated

Price target increased to kr298

Recent updates

Immunovia Streamlines Lab Operations with Move to Research Triangle Park, North Carolina

Immunovia AB Announces Positive Results from the Model-Development Study for Its Next-Generation Pancreatic Cancer Detection Test

Immunovia Successfully Develops Assays to Measure Targeted Proteomedix for Its Next-Generation Pancreatic Cancer Test - Moving Forward Towards Model-Development Study

Full year 2023 earnings released: kr7.95 loss per share (vs kr7.43 loss in FY 2022)

Immunovia AB (publ) to Report Q3, 2024 Results on Nov 14, 2024

Immunovia AB (Publ) Elects Melissa Farina and Valerie Bogdan-Powers as New Board Members

Third quarter 2023 earnings released: kr0.91 loss per share (vs kr1.01 loss in 3Q 2022)

Immunovia Successfully Completes Discovery Phase of Next-Generation Test Development

Immunovia to Significantly Restructure to Focus Resources on its Next-Generation Blood Test for Pancreatic Cancer Detection

New major risk - Revenue and earnings growth

Immunovia AB (publ) Announces Board Changes

First quarter 2023 earnings released: kr2.28 loss per share (vs kr1.95 loss in 1Q 2022)

Immunovia AB (Publ) Announces Board Changes

Philipp Von Hugo Resigns from Immunovia's Board at His Own Request

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Here's Why We're Watching Immunovia's (STO:IMMNOV) Cash Burn Situation

Forecast to breakeven in 2024

Immunovia Realigning Swedish Operations with Strategic Priorities and its Focus on the US Commercialization of the Immray Pancan-D Test

Immunovia AB (Publ) Appoints Lara E. Sucheston-Campbell as the Head of Clinical and Medical Affairs, Effective February 1, 2023

We're Keeping An Eye On Immunovia's (STO:IMMNOV) Cash Burn Rate

Immunovia Inc. Appoints Jon Hager as New National Sales Director

Forecast to breakeven in 2024

Price target decreased to kr110

Immunovia AB (publ), Annual General Meeting, Apr 27, 2023

Immunovia AB (Publ) Announces Appointment of Nomination Committee for the 2023 Annual General Meeting

Immunovia AB Announces Executive Management Team Appointments

Immunovia AB Announces Positive Update on Physician Experience Program with IMMrayTM PanCan-d

Immunovia AB Issues Preliminary Payment Rate Determination for IMMray PanCan-D Test

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Immunovia, Inc. Receives Clinical and Public Health Laboratory License from California Dept of Public Health for IMMray Pancan-d Test

Immunovia AB Announces PanDIA-1 Study for Early Detection of Pancreatic Cancer in Newly Onset Type Diabetics Moves into Next Phase

Immunovia AB Announces Results from PanFAM-1 Study

Immunovia AB (publ) Announces Executive Changes

Immunovia Names Philipp Mathieu as Chief Executive Officer

Immunovia AB Appoints Natalie Carfora as Head of Market Access US Subsidiary

Is Immunovia (STO:IMMNOV) In A Good Position To Invest In Growth?

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Immunovia AB (Publ) Announces Board Changes

Independent Director recently bought kr186k worth of stock

Price target decreased to kr215

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues miss analyst expectations

Here's Why We're Not Too Worried About Immunovia's (STO:IMMNOV) Cash Burn Situation

Third quarter 2021 earnings released: kr1.60 loss per share (vs kr1.68 loss in 3Q 2020)

Price target increased to kr298

We Think Immunovia (STO:IMMNOV) Can Afford To Drive Business Growth

Second quarter 2021 earnings released: kr2.18 loss per share (vs kr1.67 loss in 2Q 2020)

Immunovia AB (publ) Receives Approval to Begin Testing Patients for Pancreatic Cancer with the Immrayt Pancan-D Test

Chief Executive Officer recently bought kr676k worth of stock

Price target increased to kr300

Independent Director recently bought kr298k worth of stock

Independent Director has left the company

Independent Director recently bought kr192k worth of stock

First quarter 2021 earnings released: kr1.04 loss per share (vs kr1.41 loss in 1Q 2020)

Full year 2020 earnings released: kr6.84 loss per share (vs kr5.85 loss in FY 2019)

New 90-day high: kr131

What Kind Of Investors Own Most Of Immunovia AB (publ) (STO:IMMNOV)?

Iimmunovia AB (Publ) Publishes Data Sets on the Optimization Study and Commercial Test Model Study

Full year 2020 earnings released: kr6.84 loss per share (vs kr5.85 loss in FY 2019)

Earnings miss expectations

Immunovia AB (publ) to Report Q1, 2021 Results on Apr 28, 2021

Immunovia's PanFAM Prospective Study Gathers over 3000 Familial Hereditary Pancreatic Cancer Risk Samples and Will Be Analysed in the Second Half of 2021

Here's Why We're Not Too Worried About Immunovia's (STO:IMMNOV) Cash Burn Situation

New 90-day low: kr111

Immunovia AB Announces Results from Study in Their Development Pipeline

Immunovia AB (publ)'s (STO:IMMNOV) Intrinsic Value Is Potentially 72% Above Its Share Price

New 90-day low: kr111

Insider Buying: The Immunovia AB (publ) (STO:IMMNOV) Director Just Bought kr293k Worth Of Shares

Director recently bought kr144k worth of stock